IPP Bureau
Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
By IPP Bureau - March 12, 2026
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
FDA nod to first treatment for rare genetic brain disorder
By IPP Bureau - March 12, 2026
The approval comes after a systematic review of published literature
EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients
By IPP Bureau - March 12, 2026
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors
By IPP Bureau - March 12, 2026
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Zydus boosts companion diagnostics with AI-powered CGM Diasens and GlucoLive launch
By IPP Bureau - March 12, 2026
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Alcon launches Hydrus Microstent in India to transform glaucoma care
By IPP Bureau - March 11, 2026
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Roche reports Phase III persevERA breast cancer trial results
By IPP Bureau - March 11, 2026
Giredestrant shows promise despite missing primary goal
Cirena licenses breakthrough RNA synthesis technology from CU Boulder
By IPP Bureau - March 11, 2026
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results
By IPP Bureau - March 11, 2026
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Roche shareholders back full slate of proposals, approve record dividend increase
By IPP Bureau - March 11, 2026
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Codis expands UK manufacturing with groundbreaking spray dryer
By IPP Bureau - March 10, 2026
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
UK pushes space-made medicines from orbit to patients with new support package
By IPP Bureau - March 10, 2026
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
By IPP Bureau - March 10, 2026
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
By IPP Bureau - March 10, 2026
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Frontage Laboratories expands China presence with Teddy Lab acquisition
By IPP Bureau - March 10, 2026
